Products
Umikibart Biosimilar Monoclonal Antibody (HGF) for Research
Cat No.: GMP-Bios-INN-1439
Anti-HGF therapeutic antibody (Pre-made Umikibart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Umikibart (development codes YYB101/CLM-101) is a humanized monoclonal antibody targeting HGF. It is developed by Yooyoung Pharm Co and National OncoVenture and Cell Lab Med for Colorectal cancer in Phase II development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1439-1mg | 1mg | 3090 |
| GMP-Bios-INN-1439-10mg | 10mg | |
| GMP-Bios-INN-1439-100mg | 100mg | |
| GMP-Bios-INN-1439-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Umikibart biosimilar, Whole mAb, Anti-HGF Antibody: Anti-HGF/Hepatocyte growth factor/Hepatopoietin-A/Scatter factor (SF) therapeutic antibody |
| INN Name | Umikibart |
| Target | HGF |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2024 |
| Year Recommended | 2024 |
| Companies | Yooyoung Pharm Co;National OncoVenture;Cell Lab Med |
| Conditions Approved | na |
| Conditions Active | Colorectal cancer |
| Conditions Discontinued | Solid tumours |
| Production | na |
| Development Tech | na |
